Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis
Background: Long-term vedolizumab (VDZ) outcomes in real-world cohorts have been largely limited to 1-year follow-up, with few bio-naïve patients or objective markers of inflammation assessed. Objectives: We aimed to assess factors affecting VDZ persistence including clinical, biochemical and faecal...
Збережено в:
| Автори: | , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
SAGE Publishing
2024-07-01
|
| Серія: | Therapeutic Advances in Gastroenterology |
| Онлайн доступ: | https://doi.org/10.1177/17562848241258372 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|